Todd Franklin Watanabe is CEO & President at Arcutis Biotherapeutics, Inc. (ARQT). They have made 18 open-market trades across 1 company since 2020, most recently 2025-06-10.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $31K since 2023, against 16 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ARQT | 914,113 | $26.4M |
Shares reported on the most recent Form 4, priced at the 2025-06-12 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ARQT | SELL | 2025-05-02 | 2025-05-05 | $15.19 | $348K | -9.0% | -11.4% | -3.0% |
| ARQT | SELL · 10b5-1 | 2025-03-24 | 2025-03-26 | $17.54 | $64K | -12.8% | -10.9% | -12.6% |
| ARQT | SELL · 10b5-1 | 2025-03-17 | 2025-03-20 | $17.61 | $21K | -9.9% | -18.6% | -17.7% |
| ARQT | SELL | 2025-03-03 | 2025-03-04 | $13.07 | $654K | +9.5% | +21.0% | +1.0% |
| ARQT | SELL | 2025-02-03 | 2025-02-04 | $12.70 | $490K | -2.7% | +10.4% | +17.4% |
| ARQT | SELL · 10b5-1 | 2024-12-20 | 2024-12-23 | $15.17 | $228K | -2.0% | -8.7% | +15.2% |
| ARQT | SELL | 2024-11-04 | 2024-11-05 | $8.68 | $241K | -1.2% | +31.4% | +35.4% |
| ARQT | SELL · 10b5-1 | 2024-08-02 | 2024-08-05 | $9.02 | $261K | -6.6% | +14.9% | -4.2% |
| ARQT | BUY | 2024-05-31 | 2024-12-03 | $3.52 | $21K | +1.6% | +16.6% | +2.7% |
| ARQT | SELL · 10b5-1 | 2024-05-02 | 2024-05-03 | $8.74 | $241K | +16.7% | +3.2% | +19.7% |
| ARQT | SELL · 10b5-1 | 2024-03-04 | 2024-03-06 | $11.12 | $331K | -2.8% | +7.6% | -25.2% |
| ARQT | SELL · 10b5-1 | 2024-02-28 | 2024-03-01 | $10.60 | $26K | -8.1% | -19.6% | -28.1% |
| ARQT | BUY | 2023-05-31 | 2023-12-01 | $6.38 | $9K | +19.6% | +72.4% | +416.6% |
| ARQT | SELL · 10b5-1 | 2023-03-06 | 2023-03-08 | $15.26 | $37K | -13.4% | -7.4% | -35.5% |
| ARQT | SELL | 2023-02-28 | 2023-03-02 | $15.89 | $210K | -27.4% | -29.4% | -52.5% |
| ARQT | SELL · 10b5-1 | 2023-02-13 | 2023-02-15 | $17.01 | $17K | -4.3% | -34.4% | -41.0% |
| ARQT | SELL · 10b5-1 | 2023-02-01 | 2023-02-03 | $17.00 | $17K | +2.7% | -12.9% | -13.2% |
| ARQT | SELL · 10b5-1 | 2022-12-07 | 2022-12-09 | $17.06 | $17K | -17.6% | -14.5% | -24.9% |
| ARQT | SELL · 10b5-1 | 2022-11-07 | 2022-11-09 | $18.00 | $18K | -2.5% | -8.9% | -10.3% |
| ARQT | SELL · 10b5-1 | 2022-10-07 | 2022-10-11 | $19.51 | $20K | -4.7% | +6.2% | -21.1% |
| ARQT | SELL · 10b5-1 | 2022-09-07 | 2022-09-09 | $21.51 | $22K | -13.5% | -12.1% | -21.7% |
| ARQT | SELL | 2022-08-05 | 2022-08-09 | $24.74 | $124K | +2.7% | -11.6% | -26.0% |
| ARQT | SELL | 2022-07-08 | 2022-07-12 | $25.39 | $647K | -7.4% | +6.9% | -18.0% |
| ARQT | SELL · 10b5-1 | 2022-07-06 | 2022-07-07 | $22.07 | $22K | +8.0% | +8.2% | -13.3% |
| ARQT | SELL · 10b5-1 | 2022-06-06 | 2022-06-06 | $21.06 | $21K | -4.6% | +11.4% | +3.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.